Drugmaker GlaxoSmithKline, which was slapped with a record $489 million fine for corruption in China last month, said on Tuesday it was looking into allegations of corruption in the United Arab Emirates. Britain's biggest pharmaceuticals group confirmed the investigation following allegations of improper payments set out in a whistleblower's email sent to its top management on Monday.